785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) — Adi Diab (2022) | RDL Network
785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)
Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fábio Franke, Tudor‐Eliade Ciuleanu, Caio Guilherme Pereira, Eva Muñoz‐Couselo, Fernanda Damian, Michael Schenker, A. Perfetti, Célèste Lebbé, G. Quéreux, Friedegund Meier, Brendan D. Curti, Carlos A. Rojas, Yull Arriaga, Hai-Su Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary Tagliaferri, Nikhil I. Khushalani
Nikhil I. Khushalani, Adi Diab, Paolo A. Ascierto, James Larkin, Shahneen Sandhu, Mario Sznol, Henry Koon, Anthony Jarkowski, Ming Zhou, Paul Statkevich, William J. Geese, Georgina V. Long
Célèste Lebbé, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz‐Couselo, Caio Guilherme Pereira, Shahneen Sandhu, Ming Zhou, Brendan D. Curti, Nikhil I. Khushalani, Matthew Taylor, Alfonsus Van Den Eertwegh, Ute Hoch, Georgina Long AO, Yull Arriaga, Adi Diab, Helen Gogas
Helen Gogas, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz‐Couselo, Adi Diab, Caio Guilherme Pereira, G. Quéreux, Shahneen Sandhu, Brendan D. Curti, Nikhil I. Khushalani, Matthew H. Taylor, Gregory A. Daniels, Anna Spreafico, Tarek Meniawy, Alfons J.M. van den Eertwegh, Yongliang Sun, Yull Arriaga, Ming Zhou, Georgina V. Long, Célèste Lebbé
Discussion(0)
No comments yet. Be the first to comment.